Home » VICAL VACCINE GETS $2.6M FEDERAL GRANT

VICAL VACCINE GETS $2.6M FEDERAL GRANT

June 7, 2006

Biopharmaceutical firm Vical Inc. said Wednesday it qualifies for accelerated access to $2.6 million in funding to further develop an avian flu vaccine.
MSN Money

KEYWORDS FDAnews Drug Daily Bulletin

28Sep
The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain
28Sep
Calculating Sample Size to Satisfy FDA Expectations
11Oct
GMP Quality Management vSummit 2023: Where Quality Meets Risk
16Oct
MAGI@home Clinical Research Conference 2023
26Oct
FDA in 2024: What to Expect in an Election Year
02Nov
How UDI and UDI Data Can — and Must — Be Used for More Than Just Device Identification

VICAL VACCINE GETS $2.6M FEDERAL GRANT

Upcoming Events

The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

Calculating Sample Size to Satisfy FDA Expectations

GMP Quality Management vSummit 2023: Where Quality Meets Risk

MAGI@home Clinical Research Conference 2023

FDA in 2024: What to Expect in an Election Year

How UDI and UDI Data Can — and Must — Be Used for More Than Just Device Identification

Featured Products

FDA, FTC and DOJ Enforcement of Medical Device Regulations

Using Real-World Evidence in Drug and Device Submissions

Featured Stories

Expert Says FDA Under No Obligation to Educate Companies on Inspection Rights

FDA Deems Hamilton Ventilator Recall Class I for Software Issue Causing Device to Stop

Survey Shows Nearly All Pharm Techs Face Drug Shortages, Pfizer Plant Shortages Continue Until 2024

FDA Shares Premarket Requirements for Device Cybersecurity in Final Guidance

The Revised ICH E8: A Guide to New Clinical Trial Requirements